First phase I clinical trial of an HIV-1 subtype D gp140 envelope protein vaccine: immune activity induced in all study participants.
To combat HIV-1 diversity, we are developing a multienvelope vaccine (comprising DNA, vaccinia virus and protein vectors). Toward this goal, we conducted a phase I clinical trial of EnvPro, a gp140 protein formulated in alum. The vaccine was well tolerated and elicited an immune response in every trial participant.
Hurwitz
Julia L
JL
Department of Immunology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Lockey
Timothy D
TD
Jones
Bart
B
Freiden
Pamela
P
Sealy
Robert
R
Coleman
John
J
Howlett
Nanna
N
Branum
Kristen
K
Slobod
Karen S
KS
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D000328:Adult; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007114:Immunization; D007115:Immunization Schedule; D007273:Injections, Intramuscular; D008297:Male; D011994:Recombinant Proteins / Q000276:immunology; D054299:env Gene Products, Human Immunodeficiency Virus / Q000096:biosynthesis / Q000276:immunology*
D016915:AIDS Vaccines; D015483:HIV Antibodies; D011994:Recombinant Proteins; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1